Endpoints Manufacturing: Charles River makes a splash for cell and gene therapy specialist; 5 questions with Homology Medicines
After a blistering start to 2021, it seemed as though news in the biotech manufacturing world had slowed to a more reasonable pace in the last few weeks.
Then the news came down Wednesday of an expensive merger in one of the fastest-growing manufacturing arenas: cell and gene therapeutics. And it comes with a $875 million cash price tag.
Charles River Laboratories, a player in the field for 75 years, bought out Cognate BioServices, a cell and gene therapy specialist with operations in both North America and Europe. Pitched as an “exceptional strategic fit”, Cognate’s services will give Charles River a boost in solidifying its end-to-end manufacturing capacities for cell and gene therapies.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,900+ biopharma pros reading Endpoints daily — and it's free.